真菌与银屑病发生发展及治疗相关性研究进展

摘要/Abstract

中图分类号:

曲昱颖, 史冬梅. 真菌与银屑病发生发展及治疗相关性研究进展[J]. 中国真菌学杂志, 2021, 16(6): 423-427.

[1] WALDMAN A, GILHAR A, DUEK L, et al. Incidence of Candida in psoriasis: a study on the fungal flora of psoriatic patients[J]. Mycoses, 2001,44(3-4): 77-81.
[2] TAHERI SARVTIN M, SHOKOHI T, HAJHEYDARI Z, et al. Evaluation of candidal colonization and specific humoral responses against Candida albicans in patients with psoriasis[J]. Int J Dermatol, 2014,53(12):e555-560.
[3] PICCIANI B L, MICHALSKI-SANTOS B, CARNEIRO S, et al. Oral candidiasis in patients with psoriasis: correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment[J]. J Am Acad Dermatol, 2013,68(6):986-991.
[4] LEUNG D Y, WALSH P, GIORNO R, et al. A potential role for superantigens in the pathogenesis of psoriasis[J]. J Invest Dermatol, 1993,100(3):225-228.
[5] ARMSTRONG A W, BUKHALO M, BLAUVELT A. A clinician's guide to the diagnosis and treatment of candidiasis in patients with psoriasis[J]. Am J Clin Dermatol, 2016,17(4):329-336.
[6] DE JESúS-GIL C, SANS-DE SAN NICOLàS L, RUIZ-ROMEU E, et al. Interplay between humoral and CLA(+) T cell response against Candida albicans in psoriasis[J]. Int J Mol Sci, 2021,22(4):1519.
[7] PIETRZAK A, GRYWALSKA E, SOCHA M, et al. Prevalence and possible role of Candida species in patients with psoriasis: a systematic review and meta-analysis[J]. Mediators Inflamm, 2018,2018:9602362. DOI: 10.1155/2018/9602362.
[8] MARCINKIEWICZ M, MAJEWSKI S. The role of antimicrobial peptides in chronic inflammatory skin diseases[J]. Postepy Dermatol Alergol, 2016,33(1):6-12.
[9] ABTIN A, ECKHART L, GLäSER R, et al. The antimicrobial heterodimer S100A8/S100A9(calprotectin) is upregulated by bacterial flagellin in human epidermal keratinocytes[J]. J Invest Dermatol, 2010,130(10):2423-2430.
[10] SCHONTHALER H B, GUINEA-VINIEGRA J, WCULEK S K, et al. S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3[J]. Immunity, 2013,39(6):1171-1181.
[11] URBAN C F, ERMERT D, SCHMID M, et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans[J]. PLoS Pathog, 2009,5(10):e1000639.
[12] ELEWSKI B. Does pityrosporum ovale have a role in psoriasis[J]? Arch Dermatol, 1990,126(8):1111-1112.
[13] CHAN C S, VAN VOORHEES A S, LEBWOHL M G, et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation[J]. J Am Acad Dermatol, 2009,60(6):962-971.
[14] LOBER C W, BELEW P W, ROSENBERG E W, et al. Patch tests with killed sonicated microflora in patients with psoriasis[J]. Arch Dermatol, 1982,118(5):322-325.
[15] RUDRAMURTHY S M, HONNAVAR P, CHAKRABARTI A, et al. Association of Malassezia species with psoriatic lesions[J]. Mycoses, 2014,57(8):483-488.
[16] BARONI A, PAOLETTI I, RUOCCO E, et al. Possible role of Malassezia furfur in psoriasis: modulation of TGF-beta1, integrin, and HSP70 expression in human keratinocytes and in the skin of psoriasis-affected patients[J]. J Cutan Pathol, 2004,31(1):35-42.
[17] 邓国辉, 杨国良. 糠秕马拉色菌感染与寻常性银屑病患者血清炎性因子的关系研究[J]. 实用皮肤病学杂志,2018,11(1):5-8.
[18] SALOMON J, SZEPIETOWSKI J C, PRONIEWICZ A. Psoriatic nails: a prospective clinical study[J]. J Cutan Med Surg, 2003,7(4):317-321.
[19] SáNCHEZ-REGAñA M, UMBERT P. Diagnosis and management of nail psoriasis[J]. Actas Dermosifiliogr, 2008, 99(1): 34-43.
[20] BEUSCHER T L, KELECHI T J. Onychomycosis: diagnosis, treatment, and prevention[J]. J Wound Ostomy Continence Nurs, 2019, 46(4): 333-335.
[21] ROMASZKIEWICZ A, BYKOWSKA B, ZABłOTNA M, et al. The prevalence and etiological factors of onychomycosis in psoriatic patients[J]. Postepy Dermatol Alergol, 2018, 35(3): 309-313.
[22] VAN DER VELDEN H M, KLAASSEN K M, VAN DE KERKHOF P C, et al. Fingernail psoriasis reconsidered: a case-control study[J]. J Am Acad Dermatol, 2013, 69(2): 245-252.
[23] RUNNE U, ORFANOS C E. The human nail: structure, growth and pathological changes[J]. Curr Probl Dermatol, 1981,9:102-149. DOI: 10.1159/000403346.
[24] ELEWSKI B E. Onychomycosis: pathogenesis, diagnosis, and management[J]. Clin Microbiol Rev, 1998, 11(3): 415-429.
[25] KAçAR N, ERGIN S, ERGIN C, et al. The prevalence, aetiological agents and therapy of onychomycosis in patients with psoriasis: a prospective controlled trial[J]. Clin Exp Dermatol, 2007, 32(1): 1-5.
[26] ZAIAS N. Psoriasis of the nail. A clinical-pathologic study[J]. Arch Dermatol, 1969, 99(5): 567-579.
[27] GUPTA A K, LYNDE C W, JAIN H C, et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study[J]. Br J Dermatol, 1997, 136(5): 786-789.
[28] DAWBER R. Fingernail growth in normal and psoriatic subjects[J]. Br J Dermatol, 1970, 82(5): 454-457.
[29] BALESTRI R, RECH G, PIRACCINI B M, et al. Pityriasis versicolor during anti-TNF-α monoclonal antibody therapy: therapeutic considerations [J]. MYCOSES, 2012, 55(5): 444-446.
[30] ZATTAR G A, CARDOSO F, NAKANDAKARI S,et al. Cutaneous histoplasmosis as a complication after anti-TNF use-Case report[J]. AN BRAS DERMATOL, 2015, 90(3 suppl 1): 104-107.
[31] BARDAZZI F, BALESTRI R, RECH G, et al. Dermatophytosis during anti-TNF-α monoclonal antibody therapy[J]. Mycoses, 2011, 54(5): e619-e620.
[32] VALENZUELA F, DE LA CRUZ FERNANDEZ C, GALIMBERTI R L, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study[J]. Actas dermo-sifiliograficas, 2017, 108(6): 550-563.
[33] GORDON K B, COLOMBEL J F, HARDIN D S. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis[J]. NEW ENGL J MED, 2016, 375(21): 2102
[34] SAUNTE D M, MROWIETZ U, PUIG L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management[J]. Br J Dermatol, 2017, 177(1): 47-62.
[35] CYPOWYJ S, PICARD C, MARóDI L, et al. Immunity to infection in IL-17-deficient mice and humans[J]. Eur J Immunol, 2012, 42(9): 2246-2254.
[36] LEE M P, WU K K, LEE E B, et al. Risk for deep fungal infections during IL-17 and IL-23 inhibitor therapy for psoriasis[J]. Cutis, 2020, 106(4): 199-205.
[37] ALVES N, MOREIRA T A, MALVINO L, et al. Onychomycosis in psoriatic patients with nail disorders: aetiological agents and immunosuppressive therapy[J]. Dermatol Res Pract, 2020: 7209518. DOI: 10.1155/2020/7209518.
[38] YAMAMOTO T, NISHIOKA K. Deep dermatophytosis during topical tacrolimus therapy for psoriasis[J]. Acta Derm Venereol, 2003, 83(4): 291-292.
[39] YOO, JANE Y. Black dot tinea capitis in an immunosuppressed man[J]. J Clin Aesthet Dermatol, 2013, 6(5): 49-50.
[40] BAIG M A, SHEIKH S. Erythrodermic psoriasis with superimposed fungal infection: a presentation in the emergency room[J]. 2018. DOI:10.5152/eajem.2018.57431.
[41] JAN F, ULF D, LOUISE B, et al. Scalp psoriasis: synergy between the Malassezia yeasts and skin irritation due to calcipotriol[J]. ACTA DERM-VENEREOL, 2003, 83(6): 438-441.
[42] LESAN S, TOOSI R, ALIAKBARZADEH R, et al. Oral Candida colonization and plaque type psoriasis: Is there any relationship[J]?J Investig Clin Dent, 2018,9(3): e12335.
[43] CHIU H Y, CHANG W L, TSAI T F, et al. Risk of psoriasis following terbinafine or itraconazole treatment for onychomycosis:a population-based case-control comparative ctudy[J]. Drug Saf, 2018, 41(3): 285-295.
[44] ZAOUAK A, CHAMLI A, KOUBAA W, et al. Generalized pustular psoriasis induced by terbinafine[J]. Presse Med, 2019, 48(9): 1009-1011.
[45] SZEPIETOWSKI J C. Terbinafine exacerbates psoriasis: case report with a literature review[J]. Acta Dermatovenerol Croat, 2003, 11(1): 17-21.
[46] GUPTA A K, SIBBALD R G, KNOWLES S R, et al. Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis[J]. J Am Acad Dermatol, 1997, 36(5 Pt 2): 858-862.
[47] KIM B S, JANG H S, JWA S W, et al. Generalized pustular psoriasis and hepatic dysfunction associated with oral terbinafine therapy[J]. J Korean Med Sci, 2007, 22(1): 167-169.

真菌与银屑病发生发展及治疗相关性研究进展

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李颖, 黄晶晶, 刘文静, 王培昌, 徐英春. MALDI-TOF MS自建数据库对丝状真菌临床分离株鉴定能力的评估[J]. 中国真菌学杂志, 2021, 16(6): 361-366.
[2]	尚元元, 李可心, 马春梅, 李莎莎, 扈容英, 杨文君. 定量PCR检测联合G试验及GM试验对侵袭性真菌感染早期诊断的价值[J]. 中国真菌学杂志, 2021, 16(6): 367-372.
[3]	叶俊兵, 叶利洪, 何建松, 李王坚, 李峰, 万俊彦. 尿石症患者并发真菌感染的菌群分布、药敏及危险因素分析[J]. 中国真菌学杂志, 2021, 16(6): 384-387,402.
[4]	谢朝云, 李文华, 杨忠玲. 新生儿混合性念珠菌/细菌血流感染相关因素分析[J]. 中国真菌学杂志, 2021, 16(6): 392-396.
[5]	李强, 郭健莲, 肖斌龙. 创口分泌物念珠菌的分布及其耐药性分析[J]. 中国真菌学杂志, 2021, 16(6): 397-399.
[6]	康烨, 王瑞娜, 阎澜. 抗真菌药物潜在靶点及化合物研究进展[J]. 中国真菌学杂志, 2021, 16(6): 414-419.
[7]	胡玲, 陈辉. 皮肤真菌菌群对皮肤健康影响的研究进展[J]. 中国真菌学杂志, 2021, 16(6): 420-422.
[8]	张丽, 于淑颖, 宁雅婷, 肖盟, 肖玉玲, 崔兰英, 陈中举, 严岩, 叶丽艳, 徐英春. 全国多中心血流分离近平滑念珠菌药物敏感性和分子流行病学回顾性研究[J]. 中国真菌学杂志, 2021, 16(5): 289-295.
[9]	高爱莉, 代歆悦, 李华平, 王焕丽, 马少吟, 陈教全, 朱慧兰. 外阴阴道念珠菌病患者血清及分泌物HMGB1、IL-17、IL-23表达水平及临床意义[J]. 中国真菌学杂志, 2021, 16(5): 314-318,325.
[10]	徐灵玲, 曾章锐, 丁银环, 杨葵. 川南地区侵袭性念珠菌感染流行病学及耐药性分析[J]. 中国真菌学杂志, 2021, 16(5): 319-325.
[11]	谭静文, 高志琴, 杨虹, 杨连娟. 国产泊沙康唑对生殖器来源念珠菌的体外药物敏感性研究[J]. 中国真菌学杂志, 2021, 16(5): 326-329,334.
[12]	李彩云, 柯婷婷, 李刚, 赵梅, 王文. 不同产膜能力的念珠菌对妊娠期阴道炎患者Toll样受体通路及妊娠结局的影响[J]. 中国真菌学杂志, 2021, 16(5): 330-334.
[13]	武芳, 张叶毛, 赵建平, 赵亚楠, 周秀岚. 2012—2019年某医院临床分离念珠菌的耐药性监测[J]. 中国真菌学杂志, 2021, 16(5): 341-345.
[14]	唐秀雅, 周万青. 西弗射盾子囊霉研究进展[J]. 中国真菌学杂志, 2021, 16(5): 351-355.
[15]	张欠欠, 罗传玉, 陈嘉琪, 封小川. 白念珠菌感染现状及抗真菌药物研究进展[J]. 中国真菌学杂志, 2021, 16(5): 356-360.